Ropes & Gray advised FogPharma in a collaboration with ARTBIO to co-develop new radiopharmaceuticals that would use FogPharma’s Helicon peptides platform, designed to better bind to solid tumor cancer targets and block harmful cellular signals with ARTBIO’s radiopharmaceutical AlphaDirect platform, designed to delivery radiation precisely into tumors. The collaboration seeks to produce a new category of targeted therapy on cancer cells. The transaction was announced on May 14.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associates Dan Freshman and Catherine Choi.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.